Neuracle Science Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Feb 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 20 to 28, 2027 · next Feb 20
- 1 fee due Mar 5, 2027The maintenance fee for Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma (US 11,746,149) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Anti-Family with Sequence Similarity 19, Member A5 Antibodies and Method of Use Thereof (US 11,970,532) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis (US 10,640,557) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,579,398 | Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis In force · High confidence | In force | High confidence | |
| US 10,640,557 | Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis In force · Medium confidence | In force | Medium confidence | |
| US 11,739,141 | Pharmaceutical use of FAM19A5 involved in regulating gliogenesis In force · From the USPTO record | In force | From the USPTO record | |
| US 12,435,130 | Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis In force · Medium confidence | In force | Medium confidence | |
| US 10,385,098 | Agonist of spexin-based galanin type 2 receptor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,248,023 | Agonist of spexin-based galanin type 2 receptor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,332,521 | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,202,889 | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,155,613 | Use of anti-FAM19A5 antibodies for treating fibrosis In force · From the USPTO record | In force | From the USPTO record | |
| US 12,492,246 | ANTI-FAM19A5 Antibodies and Uses Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 pending · 3 no status recorded